🔍

CONCORDBIO - Concord Biotech

📊 NSE: CONCORDBIO 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 21:09

📢 Recent Corporate Announcements

Concord Biotech to Host Group Investor Meeting on March 6, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Feb 2026, 02:26 PM

Concord Biotech Limited has scheduled a group meeting with analysts and institutional investors on March 6, 2026. The meeting is hosted by Antique Stock Broking and will take place at the company's plant in Ahmedabad starting at 11:00 AM. The discussions will focus on publicly available information, ensuring no unpublished price sensitive information is disclosed. Such plant visits often allow institutional investors to gain better operational insights into the company's manufacturing capabilities.

Meeting scheduled for March 6, 2026, starting at 11:00 AM
Hosted by Antique Stock Broking as a group meeting
Venue is the company's manufacturing plant in Ahmedabad
Compliance with SEBI Regulation 30(6) regarding investor interactions

💡 Monitor for any post-meeting transcripts or presentations that might provide qualitative insights into plant operations. No immediate trading action is required based on this routine schedule announcement.

Concord Biotech Q3 Revenue Up 14% YoY to ₹278 Cr; PAT Dips 8.5% on Exceptional Costs

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 26 Feb 2026, 02:23 PM

Concord Biotech reported a 13.9% YoY increase in revenue from operations to ₹27,813 lakhs for Q3 FY26. However, Net Profit (PAT) declined by 8.5% YoY to ₹6,778 lakhs, primarily impacted by a one-time exceptional charge of ₹327.54 lakhs related to new labour code regulations. On a sequential basis, the company showed recovery with revenue and PAT growing 12.6% and 7.8% respectively compared to Q2 FY26. The board also strengthened its leadership by appointing Mr. Paritosh Trivedi as the new Company Secretary and Compliance Officer.

Revenue from operations grew 13.9% YoY to ₹27,813.39 lakhs in Q3 FY26 compared to ₹24,422.02 lakhs in Q3 FY25.
Net Profit (PAT) for the quarter stood at ₹6,778.27 lakhs, a decline from ₹7,408.88 lakhs in the corresponding quarter last year.
Recognized an exceptional item of ₹327.54 lakhs due to the statutory impact of new labour codes on employee benefit obligations.
9-month PAT for FY26 shows a significant decline to ₹17,324.46 lakhs from ₹23,102.69 lakhs in the same period last year.
Appointed Mr. Paritosh Trivedi as Company Secretary and Compliance Officer effective February 11, 2026.

💡 Investors should monitor the margin pressure as PAT has declined despite healthy revenue growth. The significant year-to-date profit lag compared to the previous fiscal suggests a cautious outlook until bottom-line growth stabilizes.

Concord Biotech to Attend Kotak Institutional Equities Investor Conference on Feb 26, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Feb 2026, 10:20 AM

Concord Biotech Limited has announced its participation in an investor conference scheduled for February 26, 2026, in Mumbai. The event is organized by Kotak Institutional Equities and will feature both one-on-one and group meetings starting from 9:00 AM. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be discussed during these interactions. This engagement reflects the company's ongoing efforts to maintain transparency and communication with institutional investors.

Investor conference scheduled for February 26, 2026, in Mumbai.
Meetings organized by Kotak Institutional Equities starting at 9:00 AM.
Interaction format includes both 1x1 and Group Meetings.
Discussions will be strictly based on publicly available information.
The schedule is subject to change based on exigencies from either the host or the company.

💡 No immediate action is required as this is a routine disclosure. Investors should look out for any post-event presentations or transcripts that may provide further clarity on the company's growth trajectory.

Concord Biotech to Attend IIFL Capital Investor Conference on February 25, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Feb 2026, 10:13 AM

Concord Biotech Limited has scheduled an interaction with institutional investors and analysts on February 25, 2026, in Mumbai. The event is organized by IIFL Capital and will feature both one-on-one and group meeting formats starting from 11:00 AM. The company has explicitly stated that discussions will be confined to publicly available information, ensuring no unpublished price sensitive information is disclosed. This is a standard investor relations activity aimed at maintaining transparency with the financial community.

Meeting scheduled for February 25, 2026, starting at 11:00 AM IST.
Organized by IIFL Capital as part of an Investor Conference in Mumbai.
Interaction format includes both 1x1 and group meetings with institutional investors.
Company confirms no unpublished price sensitive information (UPSI) will be shared.
Disclosure made under Regulation 30(6) of SEBI LODR Regulations 2015.

💡 No immediate action is required as this is a routine disclosure. Investors should watch for any investor presentations or transcripts that may be released following the conference for updates on business outlook.

Concord Biotech Q3 FY26 Revenue Grows 14% to ₹278 Cr; API Segment Surges 24%

🔵 WATCH ⭐ 8/10

EARNINGS 📅 18 Feb 2026, 07:39 PM

Concord Biotech reported a recovery in Q3 FY26 with revenue growing 14% YoY to ₹278 crores, though 9-month revenue remains 5% lower at ₹729 crores due to H1 disruptions. The API business was a major driver this quarter, growing 24% to ₹219 crores, while the formulation segment saw a decline. Reported EBITDA margins stood at 35.6%, impacted by start-up costs for the new injectable facility; however, core margins remain healthy at 40%. Management expects a return to historical growth levels in FY27 as regulatory hurdles clear and the injectable business scales toward its ₹600 crore peak potential.

Q3 FY26 revenue increased 14% YoY to ₹278 crores, led by strong API performance of ₹219 crores.
Adjusted EBITDA margins (excluding start-up and US subsidiary costs) remained stable at 40%.
The new injectable facility received WHO GMP certification, targeting a peak revenue of ₹600 crores.
9-month PAT stood at ₹64 crores, impacted by ₹3 crores in new labor code provisions and lower other income.
Company remains debt-free with cash and bank balances of ₹350 crores as of December 31, 2025.

💡 Investors should focus on the scale-up of the injectable facility and the resumption of Middle East tenders as primary growth drivers for FY27. The stock is a recovery candidate as temporary headwinds from H1 FY26, such as CDSCO delays and tariff uncertainties, have largely been resolved.

Concord Biotech Releases Q3 FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Feb 2026, 06:31 PM

Concord Biotech Limited has officially released the audio recording of its earnings conference call for the third quarter and nine months ended December 31, 2025. The call was held on February 12, 2026, following the announcement of the company's financial results. This disclosure is a standard regulatory requirement under SEBI (LODR) Regulations to ensure all shareholders have access to management's commentary. Investors can now access the full discussion and Q&A session via the company's website.

Earnings call for Q3 and 9M FY26 conducted on February 12, 2026, at 3:30 PM IST
Audio recording link made available on the company's official website for public access
Compliance with Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
The recording covers management's discussion on financial results for the period ending December 31, 2025

💡 Investors should listen to the recording to understand management's outlook on growth and operational performance; no immediate action is required based on this routine filing.

Concord Biotech Q3 Revenue Up 14% to Rs 278 Cr; EBITDA Margins Impacted by Expansion Costs

🔵 WATCH ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 11:06 PM

Concord Biotech reported a 14% YoY revenue growth in Q3FY26, reaching Rs 278 crore, primarily driven by a 24% surge in the API segment. However, PAT declined by 16% YoY to Rs 64 crore due to commercialization expenses for the new injectable facility and setup costs for its US subsidiary, Stellon Biotech. EBITDA margins compressed to 35.6% from 40.1% a year ago, though normalized margins remain healthy at approximately 40%. The company achieved a significant milestone by receiving WHO-GMP certification for its injectable plant, paving the way for domestic market entry.

Q3FY26 Revenue grew 14% YoY to Rs 278 crore, led by robust 24% growth in the API segment.
EBITDA margins stood at 35.6%, impacted by one-time setup costs; normalized margins are at ~40%.
Received WHO-GMP certification for Unit 4 (Injectable facility), enabling domestic brand launches.
Established US subsidiary Stellon Biotech Inc. to create a direct commercial footprint in the US market.
Appointed Raviraj Karia as the new Chief Financial Officer (CFO) with 23+ years of experience.

💡 Investors should monitor the ramp-up of the new injectable facility and the performance of the US subsidiary, as these are the primary drivers for future growth despite current margin pressure. The long-term outlook remains positive due to specialized fermentation capabilities and global expansion.

Concord Biotech Updates Authorized KMPs for Materiality Disclosures

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Feb 2026, 08:46 PM

Concord Biotech Limited has updated its list of Key Managerial Personnel (KMP) authorized to determine the materiality of events under SEBI regulations. The list includes the Chairman and Managing Director, Joint Managing Director and CEO, Chief Financial Officer, and Company Secretary. This update is a procedural requirement under Regulation 30(5) of the SEBI (LODR) Regulations, 2015. The contact details for these officials have been provided for communication with stock exchanges to ensure transparency.

Board approved a modified list of 4 KMPs for determining materiality of information.
Authorized personnel include CMD Mr. Sudhir Vaid and JMD & CEO Mr. Ankur Vaid.
CFO Mr. Raviraj Karia and CS Mr. Paritosh Trivedi are also part of the authorized team.
Disclosure made pursuant to Regulation 30(5) of SEBI (LODR) Regulations, 2015.

💡 No immediate action is required as this is a routine regulatory filing. Investors should continue to focus on the company's operational performance and quarterly results.

Concord Biotech Appoints Paritosh Trivedi as Company Secretary and Compliance Officer

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 11 Feb 2026, 08:25 PM

Concord Biotech Limited has appointed Mr. Paritosh Trivedi as the Company Secretary, Compliance Officer, and Nodal Officer effective February 11, 2026. The appointment was approved during a Board meeting that also reviewed the company's financial results for the quarter and nine months ended December 31, 2025. Mr. Trivedi is an Associate Member of ICSI with approximately 5 years of experience in corporate governance across the Textile, IT, and FMCG sectors. He holds no shares in the company and is not related to any of the directors.

Appointment of Mr. Paritosh Trivedi as Company Secretary and Compliance Officer effective February 11, 2026
The appointee brings approximately 5 years of experience in regulatory compliance and statutory filings
Board concurrently approved unaudited standalone and consolidated financial results for Q3 and 9M FY26
Mr. Trivedi holds zero shares in the company and has no relationship with existing directors

💡 This is a routine administrative change and does not impact the company's business operations or fundamentals. Investors should focus on the Q3 financial results released in the same board meeting for performance insights.

Concord Biotech Approves Q3 FY26 Results; Appoints New Company Secretary

🟡 NEUTRAL ⭐ 6/10

BOARD_MEETING 📅 11 Feb 2026, 07:27 PM

Concord Biotech's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The statutory auditors, BSR & Co. LLP, issued a limited review report with an unmodified opinion, suggesting no major accounting concerns. Additionally, the company appointed Mr. Paritosh Trivedi as the new Company Secretary and Compliance Officer effective February 11, 2026. This appointment fills a key managerial personnel (KMP) role to oversee corporate governance and regulatory filings.

Board approved unaudited financial results for the third quarter and nine months ended December 31, 2025.
Statutory auditors M/s. BSR & Co. LLP issued a Limited Review Report with an Unmodified Opinion.
Mr. Paritosh Trivedi appointed as Company Secretary, Compliance Officer, and Nodal Officer.
The new appointee brings 5 years of experience in corporate compliance across Textile, IT, and FMCG sectors.
The board meeting concluded at 6:22 P.M. on February 11, 2026.

💡 Investors should examine the detailed financial tables once published to assess revenue and margin performance for Q3. The appointment of a new compliance officer is a routine administrative update and does not impact the company's fundamental value.

Concord Biotech Clarifies No Undisclosed Information Following Trading Volume Spurt

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Feb 2026, 10:03 AM

Concord Biotech Limited has responded to a query from the National Stock Exchange regarding a significant increase in trading volume. The company clarified that it is in full compliance with Regulation 30 of SEBI (LODR) Regulations, 2015. Management stated that all material events and information have been promptly disclosed to the exchanges. There is currently no undisclosed price-sensitive information or impending corporate action that would explain the volume surge.

NSE issued a surveillance letter (Ref: NSE/CM/Surveillance/16442) on February 6, 2026.
The company responded on February 9, 2026, denying any hidden material developments.
Confirmed adherence to SEBI (Listing Obligations and Disclosure Requirements) Regulations.
No pending announcements or corporate actions were identified by the management.

💡 This is a standard regulatory response to unusual market activity and contains no new material information. Investors should monitor the stock for fundamental changes rather than reacting to this clarification.

Concord Biotech Schedules Q3FY26 Earnings Call for February 12, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Feb 2026, 12:06 PM

Concord Biotech Limited has announced its earnings conference call scheduled for February 12, 2026, at 3:30 PM IST. The call will focus on the company's financial and operational performance for the third quarter and nine months ended December 31, 2025. Senior leadership, including the Chairman & Managing Director and the CEO, will be present to interact with analysts and institutional investors. The call is being coordinated by Antique Stock Broking Limited and includes international dial-in options for global investors.

Earnings call date set for February 12, 2026, at 15:30 IST
Focus on Unaudited Standalone and Consolidated results for Q3 and 9M FY26
Management representation includes CMD Sudhir Vaid, CEO Ankur Vaid, and CFO Raviraj Karia
Universal access numbers provided: +91 22 6280 1342 and +91 22 7115 8243

💡 Investors should monitor the call for management commentary on margin trends and the progress of new product filings. No immediate action is required as this is a routine scheduling announcement.

Concord Biotech Files Quarterly SEBI Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jan 2026, 10:42 AM

Concord Biotech Limited has submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the quarter ended December 31, 2025. The certificate, issued by MUFG Intime India Private Limited, confirms that the company has adhered to all regulatory requirements regarding the processing of security certificates. Notably, the Registrar reported that no requests for dematerialization or rematerialization were received during this specific quarter. This is a standard administrative filing required by all listed companies in India.

Compliance certificate submitted for the quarter ended December 31, 2025.
Registrar MUFG Intime India Private Limited confirmed zero dematerialization or rematerialization requests.
Confirms adherence to Regulation 74(5) of SEBI (Depositories and Participants) Regulations.
The filing ensures the maintenance of accurate and verified shareholding records.

💡 This is a routine regulatory disclosure with no impact on business fundamentals. No action is required from investors.

Concord Biotech to Close Trading Window from Jan 1, 2026 for Q3 FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Dec 2025, 09:50 AM

Concord Biotech Limited has announced the closure of its trading window for all designated persons and their relatives starting January 1, 2026. This move is in compliance with SEBI (Prohibition of Insider Trading) Regulations for the upcoming declaration of financial results for the quarter ending December 31, 2025. The window will remain closed until 48 hours after the board meeting where the results are approved. This is a standard administrative procedure and does not reflect on the company's operational performance.

Trading window closure effective from January 1, 2026.
Closure is related to the Unaudited Financial Results for the quarter ended December 31, 2025.
The window will reopen 48 hours after the results are officially declared to the exchanges.
Restriction applies to all Designated Persons and their immediate relatives as per the Company's Code of Conduct.

💡 No action is required as this is a routine regulatory filing. Investors should monitor for the future announcement of the board meeting date to review the company's Q3 performance.

Concord Biotech CS & Compliance Officer Hina Patel Resigns Effective Jan 21, 2026

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 24 Dec 2025, 05:31 PM

Concord Biotech Limited has announced the resignation of Ms. Hina Patel from her position as Company Secretary and Compliance Officer, which is a Key Managerial Personnel (KMP) role. The resignation was tendered on December 24, 2025, and she will be relieved of her duties on January 21, 2026. The reason for her departure is to pursue professional opportunities outside the organization. The company now has a transition period of approximately one month to appoint a successor and ensure regulatory continuity.

Ms. Hina Patel resigned as Company Secretary and Compliance Officer (KMP) on December 24, 2025.
The official date of cessation is set for the close of business hours on January 21, 2026.
The resignation is attributed to the pursuit of external career opportunities.
The company has initiated the transition process to ensure a smooth handover of responsibilities.

💡 This is a routine administrative change and does not affect the company's business fundamentals. Investors should simply monitor for the timely appointment of a qualified successor to maintain governance standards.

View All CONCORDBIO Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Revenue for Q2 FY26 was INR 247 Cr, representing a 20% YoY decline but a 21% QoQ growth. H1 FY26 revenue stood at INR 451 Cr. While specific percentage splits for APIs vs. Injectables were not disclosed, management noted that injectable revenues are currently building up following the March 2025 commissioning.

Geographic Revenue Split

Geographic split includes India, Emerging Markets (EMs), and the US. Subdued Q2 performance was specifically linked to a deferment of a government tender in the Middle East and a shift in procurement patterns from US customers due to tariff uncertainties.

Profitability Margins

Gross margins expanded by 480 basis points YoY in Q2 FY26. EBITDA margin was reported at 36%, which was impacted by commercialization expenses for the new injectable facility. Excluding these expenses, the core EBITDA margin stood at 41%.

EBITDA Margin

Reported EBITDA margin of 36% in Q2 FY26, down from a normalized 41% due to the ramp-up of the new injectable facility commissioned in March 2025.

Capital Expenditure

The company commissioned a new injectable facility in March 2025. While the specific INR Cr value for this capex was not disclosed in the snippets, management indicated that future growth will be driven by the utilization of this new capacity.

Credit Rating & Borrowing

As of July 23, 2025, ICRA reaffirmed a long-term rating of [ICRA]AA- (Stable) and a short-term rating of [ICRA]A1+ for total bank loan facilities of INR 125.00 Cr.

⚙️ Operational Drivers

Raw Materials

Fermentation-based media and semi-synthetic API precursors. Specific chemical names like glucose or specific solvents were not disclosed in the available documents.

Import Sources

Not specifically disclosed, though the company operates in global markets including the US and Middle East, implying global sourcing for certain precursors.

Capacity Expansion

Commissioned a new injectable facility in March 2025. Management is focusing on scaling up utilization of this facility and its established fermentation platform to drive a 25% CAGR.

Raw Material Costs

Raw material costs are managed through backward integration, which management cites as a key factor in maintaining an impeccable compliance record and competitive advantage.

Manufacturing Efficiency

Core EBITDA margin of 41% (excluding new facility startup costs) indicates high manufacturing efficiency in the established API business.

📈 Strategic Growth

Expected Growth Rate

25%

Growth Strategy

The 25% CAGR will be achieved by ramping up capacity utilization at the new injectable facility commissioned in March 2025, expanding the CDMO (Contract Development and Manufacturing Organization) business for fermentation and semi-synthetic APIs, and increasing geographic reach in the US and Emerging Markets.

Products & Services

Fermentation-based APIs, Semi-Synthetic APIs, and Injectable formulations.

Brand Portfolio

Concord Biotech.

New Products/Services

Injectables, which began commercialization in March 2025 and are expected to be a major contributor to the 25% CAGR target.

Market Expansion

Targeting expansion in India, Emerging Markets, and the US by leveraging existing global player relationships.

Market Share & Ranking

Leading supplier of fermentation-based API products in a distinct niche.

Strategic Alliances

Positioned as a trusted CDMO partner for global pharmaceutical players.

🌍 External Factors

Industry Trends

The industry is seeing a shift toward specialized fermentation-based APIs where entry barriers are high due to process complexity. Concord is positioning itself to capture this through its CDMO model and new injectable capacities.

Competitive Landscape

Operates in a niche fermentation-based API space with few competitors capable of matching their scale and regulatory compliance record.

Competitive Moat

Sustainable moat built on deep expertise in complex fermentation, backward integration, and a robust regulatory approval record, which creates significant entry barriers for competitors.

Macro Economic Sensitivity

Sensitive to US trade policies and tariffs, which caused a shift in procurement patterns from US customers in Q2 FY26.

Consumer Behavior

Not applicable as the company is a B2B pharmaceutical supplier.

Geopolitical Risks

High sensitivity to Middle East conflicts, which led to the deferment of supplies under a government contract in that region.

⚖️ Regulatory & Governance

Industry Regulations

Operations are heavily dependent on CDSCO (Central Drugs Standard Control Organization) Written Confirmations for product sales and exports. Delays in these renewals directly caused the Q2 FY26 revenue decline.

Legal Contingencies

The company reported no instances of significant fraud involving management or employees for the year ended March 31, 2025.

⚠️ Risk Analysis

Key Uncertainties

Regulatory delays (CDSCO renewals) and geopolitical instability (Middle East conflict) are primary uncertainties that can cause timing-related revenue fluctuations of ~20% as seen in Q2 FY26.